GlassScriptPhysician profile
Caitlin R Beach
NPI 1801133970
$7,512.24
in general payments reported to CMS, 2019-2025
29 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088 · 2022: $1,443 · 2023: $1,812 · 2024: $1,825 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,810 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,810.41 |
| Education | $170.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.04 | 2021-2025 | |
| Janssen Biotech, INC. | $847.46 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $755.05 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $677.23 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $671.08 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Genzyme Corporation | $632.49 | 2021-2025 | |
| Lilly USA, LLC | $434.58 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $301.97 | 2023-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.83 | 2022-2025 | Spevigo |
| Pfizer INC. | $266.38 | 2021-2024 | |
| Galderma Laboratories, L.P. | $189.82 | 2021-2024 | Aklief |
| Genentech USA, INC. | $187.53 | 2021-2022 | |
| Amgen INC. | $179.49 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $160.92 | 2021-2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $150.99 | 2023-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $143.99 | 2025 | Sofdra |
| Leo Pharma INC. | $109.93 | 2022-2025 | Adbry |
| Fresenius Kabi USA, LLC | $77.79 | 2024 | Idacio |
| Ucb, INC. | $60.47 | 2025 | Bimzelx |
| Almirall LLC | $41.55 | 2021-2022 | |
| Dermavant Sciences, INC. | $40.24 | 2023 | Vtama |
| Organon LLC | $27.60 | 2025 | Vtama |
| Journey Medical Corporation | $24.68 | 2022 | |
| Paratek Pharmaceuticals, INC. | $24.56 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.40 | 2022 | |
| Glaxosmithkline, LLC. | $20.71 | 2023 | Shingrix |
| Kyowa Kirin, INC. | $16.80 | 2022 | |
| Epi Health, LLC | $15.79 | 2022 | |
| Dermira, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.